Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the <scp>RECOMB</scp> study

Esteban Ribera(Hospital Terrassa), Estebán Martínez(Instituto de Salud Carlos III), Vicente Estrada(Instituto de Salud Carlos III), Adrián Curran(Lexington City Schools), Rafael Rubio(Research Institute Hospital 12 de Octubre), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Juan Berenguer(Instituto de Salud Carlos III), José Sanz, Sarah Arterburn(Gilead Sciences (United States)), María Larrousse(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), ML Álvarez(Gilead Sciences (Spain)), Federico Pulido(Bellvitge University Hospital), Pedro Eitz Ferrer(Gilead Sciences (Spain)), Eugènia Negredo(Universitat de Vic - Universitat Central de Catalunya)
HIV Medicine
January 9, 2013
10.1111/hiv.12011
Cited by 12

Related Papers

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799